Advertisement

Topics

Latest Infectious-diseases NewsRSS

22:13 EDT 19th September 2017 | BioPortfolio

AHRQ Awards $34 Million to Expand Fight Against Healthcare-Associated Infections

  ROCKVILLE, Md., Nov. 2, 2011 /PRNewswire-USNewswire/ -- The U.S. Department of Health and Human Services' (HHS) Agency for Healthcare Research and Quality (AHRQ) announced today that it has awarded $34 million in fiscal year 2011 for grants and contracts to hospitals, academic medical institutions, and health care research organizations to expand the fight against healthcare-associat...

As care shifts from hospital to home, guarding against infection falls to families

Families are taking on more complex, risky medical tasks for their loved ones, but some parents say hospitals have not provided enough training.

Transgene: First Patient Treated in a Phase 1b/2 Trial of TG4001 in Combination with Avelumab in HPV-Positive Cancers

Clinical Trial in Collaboration with the Alliance between Merck KGaA, Darmstadt, Germany, and Pfizer First Results Expected in 2018 Transgene (Paris:TNG), a biotech company that designs and develops viral-based immunotherapies, today announces that the first patient has been treated at the Curie Institute, Paris, France, in a Phase 1b/2 ...

Taiga Biotechnologies Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 23082017] Prices from USD $250

SummaryTaiga Biotechnologies Inc Taiga Biotech is a biopharmaceutical company that develops protein and cellular therapies. The company develops therapies for diseases including cancers and infectious diseases. Its pipeline products include programs such as stem cell therapy and target specific Tcells. Taiga Biotech's programs are developed for diseases including HIV and influenza, and hematologic...

FluGen Announces Expanded Role for Clinical Advisory Board: Dr. Robert Belshe to Chair

Today FluGen Inc., a clinical stage vaccine company, announced that Dr. Robert Belshe was named Chairman of the Company’s Clinical Advisory Board (CAB). Along with Dr. Belshe’s appointment, FluGen is expanding the roles of all members of the CAB to guide the Company through the clinical development of RedeeFlu™. The Company is focused on the developm...

Global Human Papillomavirus Infection Drug Market & Clinical Trials Insight 2023

LONDON, Sept. 19, 2017 /PRNewswire/ -- "Global Human Papillomavirus Infection Drug Market & Clinical Trials Insight 2023" report gives comprehensive insight on the ongoing market and clinical development in HPV drug market.Download the full report: https://www.reportbuyer.com/product/5107306Report highlights the trends in the global HPV drug market and gives detailed overview on the HPV drug c...

Swine flu may double risk for type 1 diabetes

Norwegians aged 30 years or younger infected with the H1N1 influenza virus during the pandemic were twice as likely to develop type 1 diabetes vs. the general population, according to findings presented at the European Association for the Study of Diabetes Annual Meeting. “Our findings support a suggested role of respiratory infections in the etiology of type 1 diabetes,” Paz Lopez-Doriga Ruiz...

Biosafe Defenses LLC Announces a New Groundbreaking Disinfectant after 10 Years of Research

Biosafe Defenses LLC (formerly Biosafe Technologies LLC), the world leader in the creation of an entirely new class of light-activated disinfectants, antibacterials and biocides for the home, hospitals and industry, has just announced the receipt of a critical ninth US Patent, entitled “Conjugated Polyelectrolytes and Methods of Using the Same.” U.S. P...

Homeless ‘tent cities’ ripe for infectious disease outbreaks

Arkis BioSciences® Achieves FDA Clearance of its CerebroFlo™ EVD Catheter with Endexo® Technology

KNOXVILLE, Tenn., Sept. 19, 2017 /PRNewswire/ -- Arkis BioSciences, a leading innovator in minimally invasive surgical instrumentation, has obtained FDA clearance of its new external ventricular drainage catheter, CerebroFlo™.  According to Chad Seaver, CEO of Arkis BioSciences, the new catheter will be used for insertion into a ventricular cavity of the brain for external drainage of ...

IDbyDNA and ARUP Laboratories Introduce Explify Respiratory: Breakthrough Technology to Diagnose Pneumonia Caused by Previously Undetected Pathogens

Metagenomics test identified pathogens missed by conventional lab tests in 44 percent of immunocompromised children treated for respiratory infection ARUP Laboratories and

Former CDC Chief Launches $225 Million Global Health Initiative

Mike Bloomberg, Mark Zuckerberg, and Bill Gates team up to combat the global burdens of heart disease and infectious epidemics. SOURCE: Bloomberg DESCRIPTION:By Lena H. Sun Tom Frieden, former director of the Centers for Disease Control and Prevention, is starting a new initiative to tackle some of global health’s thorniest issues: cardiovascular disease and epidemics. Frieden, a former New Yo...

Cambodia and Laos eliminate trachoma as a public health problem

RESEARCH TRIANGLE PARK, N.C., Sept. 19, 2017 /PRNewswire-USNewswire/ -- The ministries of health of Laos and Cambodia have eliminated trachoma as a public health problem according to a recent announcement by the World Health Organization (WHO). Only three trachoma endemic countries achieved elimination before Laos and Cambodia. Trachoma is a bacterial eye infection that can caus...

Global Infectious Diseases Partnering 20102017: Deal trends, players and financials [Report Updated: 01092017] Prices from USD $3495

Global Infectious Diseases Partnering 2010 to 2017 provides the full collection of Infectious Diseases disease deals signed between the world's pharmaceutical and biotechnology companies since 2010. Trends in Infectious Diseases partnering dealsFinancial deal terms for headline, upfront and royalty by stage of developmentInfectious Diseases partnering agreement structureInfectious Diseases partner...

InDevR Licenses Mount Sinai Influenza Antibodies for VaxArray® Neuraminidase Potency Assay

BOULDER, Colo., Sept. 19, 2017 /PRNewswire/ -- InDevR, a Boulder-based progressive analytical technology and life science instrumentation company today announced that it has entered into an exclusive, world-wide license agreement for monoclonal antibodies developed by scientists at the Icahn School of Medicine at Mount Sinai. The license agreement with Mount Sinai will provide InDevR wit...

In the 'Broadband Commission', KT proposed to create a Working Group Epidemic Preparedness, preventing the spread of infectious disease through ICT technologies

SEOUL, South Korea, Sept. 19, 2017 /PRNewswire/ -- KT (CEO Chang-gyu Hwang, www.kt.com) announced that it proposed the creation of the ICT-based working group Epidemic Preparedness, preventing the spread of the infectious diseases through ICT technologies, during the UN 'Broadband Commission for Sustainable Development' meeting on the 17th of September. The Commission, was establishe...

Flu Shots: Here We Go Again!

The many myths about flu shots continue to circulate and persuade some people not to get a flu shot. Flu shots are excellent insurance, safe and reasonably effective. Immunization protects not only the recipient but also vulnerable groups in the community.

Three Ways to Lower Mortality Associated with Staphylococcus aureus Bacteremia

Choose the right antibiotics, order an echocardiogram, and consult Infectious Diseases!

InDevR Licenses Influenza Antibodies For VaxArray Neuraminidase Potency Assay

  Life Sciences Jobs   ...

Surgeons address need for payment strategy for drop therapy alternative

Today, most patients undergoing cataract surgery must self-administer multiple eye drops pre- and postoperatively. Surgeons often prescribe an antibiotic, a steroid and an NSAID to prevent infection and inflammation after cataract surgery. According to data from the U.S. Census Bureau and the National Eye Institute, CMS will fund more than 38 million cataract surgeries over the next decade. Projec...

In patients with RA who fail one TNFi, risk of serious infection is similar between rituximab, second TNFi treatment

British Unicorn Gets $40M Boost from Bill & Melinda Gates Foundation

The Bill & Melinda Gates Foundation have injected $40M (€33M) into Immunocore to accelerate the development of its immunotherapies for infectious diseases. Investment from the Bill & Melinda Gates Foundation will support the development of Immunocore’s ImmTAV and ImmTAB TCR-based technologies, ... This awesome article British Unicorn Gets $40M Boost from Bill & Melinda Gates ...

IRIS: Pioglitazone prevents secondary CV events in high-risk patients

Nondiabetic, insulin-resistant patients at elevated risk for stroke or MI derive a greater benefit from pioglitazone compared with those at lower risk, but fracture risk is also higher, according to a secondary analysis of data from the IRIS trial. Walter N. Kernan, MD, professor of medicine at Yale School of Medicine, and colleagues enrolled 3,876 participants (mean age, 63 years) with qual...

Concentra Helps Educate Patients on What's New with Flu

DALLAS, Nov. 15, 2011 /PRNewswire/ -- During the past few years, flu activity in the U.S. has seen some dramatic changes, both in preventive measures and ways to treat the virus, leaving many to question the need for flu protection.  As one of the nation's largest providers of urgent care services, Concentra is helping to educate the public about What's New with Flu, and the proper ways to st...

Roche Diagnostics Supports Fight Against MRSA as a Sponsor of Annual World MRSA Day on October 1

INDIANAPOLIS, Sept. 28, 2011 /PRNewswire/ -- As part of its ongoing work in the prevention and control of serious infections in healthcare settings, Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today its sponsorship of the 3rd Annual World MRSA Day. The kick-off event and global MRSA summit will be held on October 1, 2011, at Loyola University Stritch School of Medicine in Maywood, Ill. Organized...

Quick Search
Advertisement
 

review and buy Infectious-diseases market research data and corporate reports here